Everything below concerns c-Met receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-03. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
=== Magnetotaxis === The movement and orientation of "Ca. M. multicellularis" appears to be altered by many external stimuli as it undergoes magnetotaxis, photokinesis, negative phototaxis and potentially helical klinotaxis. The organism contains multiple internal magnetosomes, membrane-bound structures containing magnetic nanocrystals. In "Ca. M. multicellularis" these crystals are greigite (Fe3S4) but in most other species of multicellular magnetotactic bacteria (MMB) the crystals are magnetite (Fe3O4). These magnetosomes are organised in linear chains that allow the consortium to orient itself along the Earth's geomagnetic field. In samples from the Southern Hemisphere, "Ca. M. multicellularis" exhibits a preference for south-facing orientation while swimming. In weak magnetic fields, under 80 μT, "Ca. M. multicellularis" behaves differently to other magnetotactic bacteria. Under fields close to or weaker than Earth's geomagnetic field, its trajectories appear significantly scattered away from the exact magnetic field line. In these situations, movement relies mostly on a combination of other environmental factors and the direction of the magnetic field line does not fully control the final swimming direction.
Ideology, values or interests Applied, empirical or synthesis research Theoretical or academic research According to the National Institute for Research Advancement, a Japanese policy institute, think tanks are "one of the main policy actors in democratic societies ..., assuring a pluralistic, open and accountable process of policy analysis, research, decision-making and evaluation". A study in early 2009 found a total of 5,465 think tanks worldwide. Of that number, 1,777 were based in the United States and approximately 350 in Washington, DC, alone.
The excess of said expense, compared to the average cost of neighboring countries, was close to 0.79% of GDP. A Fedesarrollo study stated that the spending on defense and security carried out during 2004 "represented 4.5% of GDP", which does not have precedents in the history of Colombia. This is directly related to the Democratic Security Policy (Política de seguridad democrática) undertaken by the government of then-president Álvaro Uribe, who focused on military strikes on groups outside the law in order to regain security national. For the year 2004, the expenses of the Colombian Government in war and security were 6.59%, placing the country between the tenth that invest the most in war as a proportion of GDP.
Although most of its ecological habitats are still intact, there is an increasing population with industrial and tourism development. This is putting more pressure on the vegetation through the process of logging, overgrazing, woodcutting and infrastructure of development plans. Though the tree is widespread, it has become fragmented with the development that has occurred in its habitats. Many of its populations are suffering poor regeneration. Human activities have greatly reduced the population through overgrazing, and feeding the flowers and fruits to the livestock of the island. One of the greatest threats is the gradual drying out of the Socotra Archipelago, which has been an ongoing process for the last few hundred years. This has resulted in non-flourishing trees, and the duration of the mist and cloud around the area seems to also be decreasing. Increasingly arid environments are predicted to cause a 45 percent reduction in the available habitat for D. cinnabari by 2080. Another threat comes from goat grazing in the area, which prevents regeneration and prevents seedlings developing in locations other than rocky outcrops. Additional threats include harvesting of its resin and use of its leaves as fodder during the dry season. Presently some trees have been used to make beehives. This was generally prohibited; this displays how the species may be threatened by a breakdown in the traditional practices of the island. The best preserved and largest stand of D. cinnabari is on the limestone plateau named Rokeb di Firmihin.
Sources: en.wikipedia.org
Extremophile – Organisms capable of living in extreme environments Ombrophobe – Plant adverse to rainfall Osmophile – Organism tolerant osmotic effects from a low water activity Xerocole – Any animal adapted to live in the desert Xerophyte – A plant adapted to a hot dry environment
=== Static function tests === Given the complicated nature of the "clamp" technique (and the potential dangers of hypoglycemia in some patients), alternatives have been sought to simplify the measurement of insulin resistance. The first was the Homeostatic Model Assessment (HOMA), and more recent methods include the Quantitative insulin sensitivity check index (QUICKI) and SPINA-GR, a measure for insulin sensitivity. All of these calculated markers employ fasting insulin and glucose levels to calculate insulin resistance, and all correlate reasonably with the results of clamping studies.
His company teamed up with the Orchestre de la Suisse Romande (OSR) to record the world's first holographic symphonic performance presented at Artgenève 2024. In 2025, Orunesu's company, Cybel’Art, developed and launched Virtual Hall, a virtual reality application designed for symphonic performances, belonging to Orchestre de la Suisse Romande. The platform enables users to view concerts from various on-stage perspectives using 360-degree immersive video. Orunesu is credited as the architect and inventor of the technology, which integrates multi-camera setups and synchronized audio-visual processing. Virtual Hall was first presented at Artgenève 2025. In October 2025, Orunesu used his Virtual Hall immersive technology to document a performance of Beethoven’s Ninth Symphony held to mark the 750th anniversary of Lausanne Cathedral. The project used a capture setup with 11 360-degree cameras and 33 microphones. The performance, titled “The Ninth Symphony in Nine Luminous Scenes,” was conceived by Renato Häusler (Kalalumen) and involved more than 270 participants, including musicians, choir members, and lighting technicians. In 2026, Pierluigi Christophe Orunesu, founder of Swiss ArtTech company Cybel'Art SA, collaborated with legendary Tolkien illustrator John Howe at La Tour du Fantastique in Neuchâtel, Switzerland.
=== Diagnosis of HIV infection === Each of the three widely used methods for diagnosing HIV infection has been developed using recombinant DNA. The antibody test (ELISA or western blot) uses a recombinant HIV protein to test for the presence of antibodies that the body has produced in response to an HIV infection. The DNA test looks for the presence of HIV genetic material using reverse transcription polymerase chain reaction (RT-PCR). Development of the RT-PCR test was made possible by the molecular cloning and sequence analysis of HIV genomes. HIV testing page from US Centers for Disease Control (CDC)
Methods for the incorporation of click reaction partners into systems in and ex vivo contribute to the scope of possible bioconjugation reactions. The development of unnatural amino acid incorporation by ribosomes has allowed for the incorporation of click reaction partners as unnatural side groups on these unnatural amino acids. For example, azidohomoalanine (AHA) is a methionine analog with an azide side group. This azide side group allows cycloalkynes to react to proteins that incorporate this "AHA" unnatural amino acid. In another example, "CpK" is a lysine analog. CpK has a side group including a cyclopropane alpha to an amide bond that serves as a reaction partner to tetrazine in an inverse diels-alder reaction.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.